GNOM


Genomics & Biotechnology ETF

Reasons to Consider GNOM

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Structural Tailwinds

The cost of genomic sequencing has dropped from nearly $100mm per genome in 2002 to less than $1,000 in 2020. Adoption has continued to rise, as costs plummet.1

Targeted Exposure

GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1National Human Genome Research Institute, Nov 2021

Key Information As of 12/01/22

Inception Date 04/05/19
Total Expense Ratio 0.50%
Net Assets $209.64 million
NAV $13.47
Fact Sheet

ETF Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

ETF Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Trading Details As of 12/01/22

Ticker GNOM
Bloomberg Index Ticker SOLGNOM
CUSIP 37954Y434
ISIN US37954Y4347
Primary Exchange Nasdaq
Shares Outstanding 15,560,000
Number of Holdings 40
30-Day Median Bid-Ask Spread 0.38%

Distributions As of 12/01/22

30-Day SEC Yield -0.30%
Distribution Frequency Semi-Annually

ETF Prices As of 12/01/22

NAV $13.47 Daily Change $0.02 0.12%
Market Price $13.51 Daily Change $0.01 0.07%

Performance History

As of recent
(09/30/22)
As of recent
(09/30/22)
Fund NAV Market Price Index
1 Year -43.51% -43.60% -43.28%
3 Years 0.30% 0.32% 0.76%
Since Inception -5.50% -4.94% -5.04%
1 Year -38.58% -38.53% -38.35%
3 Years -0.10% -0.10% 0.36%
Since Inception -4.09% -3.57% -3.63%
Year-to-Date -36.80% -36.78% -36.62%
1 Month -9.67% -9.26% -9.59%
3 Months 2.20% 2.70% 2.31%
Since Inception -17.93% -16.19% -16.53%
Year-to-Date -33.67% -33.75% -33.47%
1 Month 4.95% 4.78% 4.98%
3 Months -7.59% -7.65% -7.50%
Since Inception -13.86% -12.19% -12.37%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 12/01/22

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
5.46 TXG 10X GENOMICS INC-CLASS A BKS3RS7 39.57 290,940 11,512,495.80
4.74 BNTX BIONTECH SE-ADR BK6H543 169.47 59,010 10,000,424.70
4.39 TECH BIO-TECHNE CORP BSHZ3Q0 86.41 107,196 9,262,806.36
4.36 QGEN QIAGEN N.V. BYXS688 50.46 182,080 9,187,756.80
4.35 A AGILENT TECHNOLOGIES INC 2520153 156.12 58,747 9,171,581.64
4.29 BMRN BIOMARIN PHARMAC 2437071 103.02 87,824 9,047,628.48
4.20 ALNY ALNYLAM PHARMACE B00FWN1 220.25 40,239 8,862,639.75
4.13 SRPT SAREPTA THERAPEUTICS INC B8DPDT7 122.98 70,763 8,702,433.74
3.77 CRSP CRISPR THERAPEUTICS AG BDHF4K6 54.34 146,536 7,962,766.24
3.75 ARWR ARROWHEAD PHARMA BYQBFJ8 32.02 246,934 7,906,826.68
3.70 BEAM BEAM THERAPEUTICS INC BK6L288 45.83 170,099 7,795,637.17
3.65 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 2.52 3,056,018 7,692,098.27
3.64 PACB PACIFIC BIOSCIEN B4N8MH9 11.08 693,946 7,688,921.68
3.63 RARE ULTRAGENYX PHARM BJ62Z18 37.81 202,366 7,651,458.46
3.57 ILMN ILLUMINA INC 2613990 220.86 34,080 7,526,908.80
3.41 NTRA NATERA INC BYQRG48 41.25 174,575 7,201,218.75
3.34 NTLA INTELLIA THERAPEUTICS INC BYZM6C2 45.80 153,909 7,049,032.20
3.30 VCYT VERACYTE INC BFTWZY0 28.83 241,367 6,958,610.61
2.55 MYGN MYRIAD GENETICS INC 2614153 20.34 264,361 5,377,102.74
2.45 MRNA MODERNA INC BGSXTS3 181.48 28,467 5,166,191.16
2.38 GILD GILEAD SCIENCES INC 2369174 87.90 57,065 5,016,013.50
1.98 VRTX VERTEX PHARM 2931034 320.76 12,989 4,166,351.64
1.83 RCKT ROCKET PHARMACEU BDFKQ07 18.39 209,410 3,851,049.90
1.77 QURE UNIQURE NV BJFSR88 26.29 142,236 3,739,384.44
1.49 RGNX REGENXBIO INC BZ0G875 23.54 133,517 3,142,990.18
1.32 VERV VERVE THERAPEUTICS INC BNKGXX2 22.57 123,776 2,793,624.32
1.21 FLGT FULGENT GENETICS INC BYQBFQ5 36.07 70,708 2,550,437.56
1.19 ALLO ALLOGENE THERAPEUTICS INC BFZNYB7 9.37 268,549 2,516,304.13
1.12 CDNA CAREDX INC BP3YM74 13.18 178,458 2,352,076.44
1.11 EDIT EDITAS MEDICINE INC BZ8FPH3 10.06 233,418 2,348,185.08
1.11 NVTA INVITAE CORP BVVCNT1 2.97 787,099 2,337,684.03
0.98 4974 JP TAKARA BIO INC B03ML21 13.14 156,753 2,059,595.81
0.93 BLUE BLUEBIRD BIO INC BBFL7S1 7.61 257,981 1,963,235.41
0.91 BNGO BIONANO GENOMICS INC BFY8K60 1.98 971,912 1,924,385.76
0.88 SRNE SORRENTO THERAPEUTICS INC BCT5QQ7 1.23 1,512,983 1,860,969.09
0.87 TSVT 2SEVENTY BIO INC BMTXV88 15.28 119,770 1,830,085.60
0.76 SGMO SANGAMO THERAPEUTICS INC 2573083 3.56 450,103 1,602,366.68
0.75 CRBU CARIBOU BIOSCIENCES INC BNYJR68 9.16 173,049 1,585,128.84
0.53 NSTG NANOSTRING TECHN BBL59X6 7.12 156,936 1,117,384.32
0.26 STOK STOKE THERAPEUTICS INC BJQ05Z6 7.33 74,027 542,617.91
-0.02 CASH 1.00 -43,606 -43,617.49
Holdings are subject to change.

Country Breakdown As of 10/31/22

Country Weight (%)
United States 81.0
Netherlands 5.4
Germany 4.6
Switzerland 3.9
China 3.7
Japan 1.2
France 0.2

Source: AltaVista Research, LLC

ETF Characteristics As of 12/01/22

Return on Equity -36.40%
Weighted Avg. Market Cap 15,904 M
2021 2022
Price-to-earnings -21.77 -13.89
Price-to-book value 4.27 6.21

Source: AltaVista Research, LLC

ETF Risk Stats As of 11/30/22

Versus Beta
S&P 500 0.95
MSCI EAFE 0.87
MSCI Emg. Mkts 0.80
Standard Deviation 30.60%

Source: AltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Back to Top